Finally, LCN2 can control metabolic homeostasis, including insulin sensitivity, hyperglycemia, and dyslipidemia through the modulation of NF‐κB, C/EBP signaling, HbA1c level, and body fat mass (Figure 2). This evidence concerns the gene CEBPA and metabolic syndrome.